NCT07297290

Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)

Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 220 (estimated)
• Sponsor: University Of Nigeria Teaching Hospital · Network
• Sex: All
• Age: 20 Years – 59 Years
• Healthy volunteers: Not accepted

Summary

Obesity is a chronic disease of global public health concern, contributing to cardiovascular disease, type 2 diabetes and certain cancers. Currently approved anti-obesity drugs and surgery are expensive and not readily available in Nigeria. Metformin, approved for type 2 diabetes, has been shown to promote weight loss among obese patients in high income countries. However, metformin's effects have not yet been demonstrated in Black African populations, which may have different genetic and environmental predispositions to obesity and to the effect of metformin. This blinded, placebo-controlled, randomized trial is determining the effect of metformin on weight loss, cardiovascular disease risk and insulin resistance in Black Nigerians.

Conditions

• Obesity and Cardiovascular Risk
• Insulin Resistance
• Obesity (Body Mass Index >30 kg/m2)

Interventions

Type	Name	Description
DRUG	Metformin	Metformin 500mg extended release tablets taken to a maximum of 1500mg once daily
DRUG	Placebo	Starch-based, identical looking placebo

Timeline

• Start date: 2025-07-23
• Primary completion: 2027-03-31
• Completion: 2027-09-30
• First posted: 2025-12-22
• Last updated: 2025-12-22

Locations

2 sites across 1 country: Nigeria